Cassava Sciences, Inc. (NASDAQ:SAVA) Shares Purchased by Raymond James & Associates

Raymond James & Associates boosted its position in Cassava Sciences, Inc. (NASDAQ:SAVA) by 0.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 74,097 shares of the company’s stock after acquiring an additional 565 shares during the quarter. Raymond James & Associates’ holdings in Cassava Sciences were worth $1,668,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. boosted its holdings in Cassava Sciences by 4.7% in the second quarter. BlackRock Inc. now owns 2,746,908 shares of the company’s stock valued at $67,354,000 after acquiring an additional 124,231 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Cassava Sciences by 0.8% in the third quarter. Vanguard Group Inc. now owns 2,268,566 shares of the company’s stock valued at $37,749,000 after acquiring an additional 18,907 shares during the last quarter. State Street Corp boosted its holdings in Cassava Sciences by 6.5% in the first quarter. State Street Corp now owns 1,058,949 shares of the company’s stock valued at $25,542,000 after acquiring an additional 64,903 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Cassava Sciences by 5.8% in the second quarter. Geode Capital Management LLC now owns 803,306 shares of the company’s stock valued at $19,697,000 after acquiring an additional 44,350 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Cassava Sciences by 0.8% in the third quarter. Northern Trust Corp now owns 373,634 shares of the company’s stock valued at $6,217,000 after acquiring an additional 2,996 shares during the last quarter. Institutional investors and hedge funds own 38.05% of the company’s stock.

Cassava Sciences Price Performance

NASDAQ:SAVA opened at $21.19 on Friday. The business’s 50-day moving average is $21.83 and its two-hundred day moving average is $19.70. Cassava Sciences, Inc. has a 12 month low of $12.32 and a 12 month high of $32.10. The firm has a market capitalization of $916.47 million, a PE ratio of -9.13 and a beta of -0.45.

Cassava Sciences (NASDAQ:SAVA) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.10). Equities analysts anticipate that Cassava Sciences, Inc. will post -2.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $124.00 target price on shares of Cassava Sciences in a report on Tuesday, March 5th.

Cassava Sciences Company Profile

Cassava Sciences, Inc, a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.